Mucin 17 CRISPR/Cas9 KO Plasmid (h): sc-404622
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Mucin 17 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Mucin 17 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Mucin 17 CRISPR/Cas9 KO Plasmid (h) | sc-404622 | 20 µg | $397.00 |
Overview
MUC17 encodes mucin 17, a membrane-tethered, heavily O-glycosylated mucin enriched on the apical surface of gastrointestinal epithelial cells where it supports the mucosal barrier and epithelial homeostasis. Mucin 17 contributes to cell-surface hydration, pathogen exclusion, and protection from mechanical and chemical stress, and it can modulate cell adhesion and signaling through interactions at the glycocalyx. Altered MUC17 expression and glycosylation patterns have been reported in inflammatory disorders of the gut and in epithelial malignancies, linking this mucin to pathways governing barrier integrity, differentiation, and stress responses. As a component of the epithelial defense interface, MUC17 is frequently studied in models of mucosal inflammation, host–microbe interactions, and tumor-associated changes in glycoprotein architecture.
Mucin 17 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MUC17 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MUC17 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MUC17 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Mucin 17 protein expression.
This CRISPR knockout system enables efficient generation of MUC17-deficient cell models for investigation of Mucin 17 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MUC17 exon(s) critical for Mucin 17 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MUC17 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Mucin 17 CRISPR/Cas9 KO Plasmid (h) and Mucin 17 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MUC17 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Mucin 17 HDR Plasmid (h) and Mucin 17 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MUC17 homology arms to support homology-directed repair at defined MUC17 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.